Trusted Resources: Education
Scientific literature and patient education texts
Analysis of Cognitive Ability and Adaptive Behavior Assessment Tools Used in an Observational Study of Patients With Mucopolysaccharidosis II
source: Orphanet journal of rare diseases
year: 2021
authors: Yee KS,Wu Y,Harrington M,Waisbren SE
summary/abstract:Mucopolysaccharidosis II (MPS II) is a rare lysosomal storage disease characterized by cognitive impairment in most patients. This post hoc analysis evaluated changes in cognitive function, adaptive behavior and functional outcomes in patients with neuronopathic MPS II over time. Fifty-five children with MPS II were enrolled in a 24-month observational study (NCT01822184). The Differential Ability Scales, second edition (DAS-II; early years battery for ages 2 years 6 months to 6 years 11 months, school age battery for ages 7 years to 17 years 11 months), Vineland Adaptive Behavior Scales, second edition (VABS-II) and the Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) were performed at baseline and 3-month intervals over 2 years. A subgroup of 38 children with a DAS-II General Conceptual Ability (GCA) score of 55-85 (below average-very low abilities) at any time during the study were included in this analysis.
organization: Takeda Development Center Americas, Inc., Cambridge, MA, USA. karen.yee@takeda.com.DOI: 10.1186/s13023-021-02118-3
read more
Related Content
-
Loss of Function of Mutant IDS Due to Endoplasmic Reticulum-Associated Degradation: New Therapeutic Opportunities fo...Mucopolysaccharidosis type II (MPS II) r...
-
A Guide to Understanding MPS II (Hunter Syndrome)MPS II belongs to a group of inherited m...
-
Divergent Developmental Trajectories in Two Siblings With Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome...Mucopolysaccharidosis type II (MPS II; H...
-
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysacc...AVROBIO, Inc., a leading clinical-stage ...
-
Hunting Hunter Syndrome: A Rare Disease Hidden Among Childhood Complaintshttps://www.youtube.com/watch?v=QJYy4wbV...
-
Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment o...Denali Therapeutics Inc., a biopharmaceu...
-
Luna and Partners Work to Accelerate Therapies for Hunter SyndromeAdvocacy organizations—the National MP...